CARM — Carisma Therapeutics Share News
0.000.00%
Last trade - 00:00- $0.01m
- -$2.77m
- $19.63m
Brief: Sesen Bio Reports Third Quarter 2022 Financial Results
Sesen Bio Inc reports results for the quarter ended in September - Earnings Summary
Sesen Bio Inc expected to post a loss of 8 cents a share - Earnings Preview
Sesen Bio falls on merger with Carisma Therapeutics
Brief: Sesen Bio, Carisma Therapeutics Announce Merger Agreement
Brief: Sesen Bio Files Stipulation Of Settlement To Settle Previously Disclosed Consolidated Derivative Lawsuits
Brief: Sesen Bio Currently Estimates It Will Incur Aggregate Restructuring Charges In Q3, Q4 Ranging About $13 Million To 14 Million
Sesen Bio Inc reports results for the quarter ended in June - Earnings Summary
Brief: Sesen Bio Inc - $161 Million In Cash, Cash Equivalents And Marketable Securities As Of June 30, 2022
Brief: Sesen Bio Terminates Master Bioprocessing Services Deal With Fujifilm Diosynth Biotech U.S.A.
Sesen Bio announces job cuts; shares up
Brief: Sesen Bio Says Restructuring Plan Includes Incremental Reduction In Workforce
U.S. STOCKS ON THE MOVE-Netflix, Kraft Heinz, travel stocks
U.S. STOCKS ON THE MOVE-Cruise stocks, Advent Technologies, Expensify Inc
Brief: Sesen Bio Announces Strategic Decision To Pause Clinical Development Of Vicineum™ In The Us
Brief: Sesen Bio Executes Asset Purchase Deal With F. Hoffmann-La Roche Ltd, Hoffman-La Roche Inc
Sesen Bio slumps after pausing development of lead drug
Brief: Sesen Bio Says Participated In A Type B Meeting With FDA
Brief: Sesen Bio Removes Proposal To Approve Amendment To Co's Restated Certificate Of Incorporation